Sam Brusco, Associate Editor08.24.22
Medtronic has launched the Onyx Frontier drug-eluting stent (DES) following recent CE mark clearance.
Onyx Frontier DES design changes include a dual-layer balloon, lower crossing profile, and increased catheter flexibility. According to Medtronic, this leads to a 16% improvement in deliverability over the previous generation without compromising radial strength.
The DES offers sizes from 2-5 mm diameters and its 4.5-5 mm sizes can be expanded to 6 mm to support extra-large vessels. Onyx Frontier inherits the same clinical data and indications of Resolute Onyx, including approval for bifurcation lesions, left main PCI, and one month of dual antiplatelet therapy (DAPT) in high bleeding risk patients.
“The Onyx Frontier DES launch demonstrates our commitment to interventional cardiologists by providing best-in-class products,” Jason Weidman, senior VP and president of Medtronic’s Coronary & Renal Denervation business unit, told the press. “Following our launch in the US, we're thrilled to provide hospitals across western Europe and the globe with the Onyx Frontier DES, which has been thoughtfully designed with physicians’ needs in mind. This launch furthers Medtronic’s goal of engineering the extraordinary, and we look forward to continuing to pursue innovation each day.”
The Onyx Frontier DES received U.S. Food and Drug Administration (FDA) approval in the United States in May.
Onyx Frontier DES design changes include a dual-layer balloon, lower crossing profile, and increased catheter flexibility. According to Medtronic, this leads to a 16% improvement in deliverability over the previous generation without compromising radial strength.
The DES offers sizes from 2-5 mm diameters and its 4.5-5 mm sizes can be expanded to 6 mm to support extra-large vessels. Onyx Frontier inherits the same clinical data and indications of Resolute Onyx, including approval for bifurcation lesions, left main PCI, and one month of dual antiplatelet therapy (DAPT) in high bleeding risk patients.
“The Onyx Frontier DES launch demonstrates our commitment to interventional cardiologists by providing best-in-class products,” Jason Weidman, senior VP and president of Medtronic’s Coronary & Renal Denervation business unit, told the press. “Following our launch in the US, we're thrilled to provide hospitals across western Europe and the globe with the Onyx Frontier DES, which has been thoughtfully designed with physicians’ needs in mind. This launch furthers Medtronic’s goal of engineering the extraordinary, and we look forward to continuing to pursue innovation each day.”
The Onyx Frontier DES received U.S. Food and Drug Administration (FDA) approval in the United States in May.
